[Testosterone and the metabolic syndrome]

Area of Science:

• Endocrinology
• Metabolic Health
• Cardiovascular Risk

Background:

• Low testosterone levels are associated with abdominal obesity, metabolic syndrome, and type 2 diabetes mellitus.
• Androgen ablation therapy negatively impacts insulin sensitivity and body fat mass.
• Testosterone's effects on lipid metabolism vary, with supraphysiological doses potentially lowering HDL levels.

Purpose of the Study:

• To evaluate the significance of testosterone treatment in patients with metabolic syndrome and type 2 diabetes mellitus.
• To assess the impact of testosterone administration on metabolic control in hypogonadal men.

Main Methods:

• Review of existing investigations on patients undergoing androgen ablation therapy.
• Analysis of studies examining testosterone's effects on insulin sensitivity, body fat mass, lipid metabolism, and glycemic control.
• Consideration of data from randomized prospective trials.

Main Results:

• Physiological testosterone doses have minimal impact on lipid metabolism, while supraphysiological doses may reduce HDL levels.
• Data on testosterone's effect on glycemic control in type 2 diabetes are inconsistent; some studies show positive effects.
• Testosterone administration in hypogonadal men with metabolic syndrome appears promising for improving metabolic control.

Conclusions:

• The role of testosterone treatment in metabolic syndrome and type 2 diabetes requires further investigation through larger, randomized trials.
• Testosterone therapy is a potentially beneficial option for hypogonadal men with metabolic syndrome, aiming to enhance metabolic control.